Clinical trial
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2…
NCT00327418 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00327418 |
|---|---|
| Title | CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events |
| Official title | A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS) |
| Acronym | CARDS |
| Lead sponsor | Pfizer, Industry |
| Collaborators | Diabetes UK Department of Health, United Kingdom |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Major Coronary Event, Cerebrovascular Accident, Coronary Artery Bypass Graft, Angina, Unstable, Revascularization |
| Intervention type | Drug |
| Interventions | Atorvastatin |
| Enrollment | 2,800 |
| Start date | Jan 1, 1997 |
| Completion | Feb 1, 2004 |
| First posted | May 18, 2006 |
| Last update posted | May 10, 2007 |
| Countries | United Kingdom |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: